Drug Detail

Information about Tyvyt

Generic Name	Sintilimab
IND
Brand Name (US)	Tyvyt
Manufacturer	Innovent
Drug Type
Delivery	Intravenous
Approval Status
Indications
Overall Strategy	Immunotherapy
Strategy	Immune checkpoint inhibitor
Drug Category	PD-1 inhibitor

Sintilimab (marketed as Tyvyt) is
a humanized PD-1 inhibitor monoclonal antibody developed by Innovent and Eli Lilly, used primarily in China to treat various cancers, including relapsed/refractory classical Hodgkin's lymphoma and non-small cell lung cancer. It works by blocking the PD-1/PD-L1 pathway to enhance T-cell-mediated immune response against tumor cells.